Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals has priced an offering of
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced a proposed private offering of $200 million in convertible senior notes due 2029, with an option to purchase an additional $30 million. The notes are senior, unsecured obligations, maturing on May 1, 2029, and holders can convert them under certain circumstances. Mirum plans to use net proceeds primarily to repurchase revenue interests amounting to approximately $192.7 million and for general corporate purposes, including working capital and potential acquisitions. The offering is subject to market conditions and will not be registered under the Securities Act. Forward-looking statements indicate risks regarding market conditions and the successful application of proceeds.
Mirum Pharmaceuticals (MIRM) reported preliminary financial results for Q1 2023, with total revenue of approximately
On April 10, 2023, Mirum Pharmaceuticals (NASDAQ: MIRM) announced the granting of inducement awards to five new employees, including non-qualified stock options for 25,950 shares and 12,960 restricted stock units (RSUs), under its 2020 Inducement Plan. The options have an exercise price of
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has appointed Tim Walbert to its Board of Directors, effective immediately. Walbert previously led Horizon Therapeutics and is recognized for his extensive experience in the biopharmaceutical industry. Niall O’Donnell, a director since November 2018, will step down during the upcoming 2023 Annual Meeting of Stockholders on June 12, 2023. Walbert aims to leverage his expertise in rare diseases to enhance Mirum's growth, particularly in developing therapies for debilitating liver conditions. The company’s existing product, LIVMARLI, is approved for cholestatic pruritus in patients with Alagille syndrome, with additional approvals pending. Chairman Mike Grey expressed confidence in Walbert’s contributions to bolster Mirum's market position in treating rare diseases.
Mirum Pharmaceuticals has submitted a variation application to the European Medicines Agency (EMA) to extend the Marketing Authorization for LIVMARLI (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC) in patients aged two months and older. This is based on data from the Phase 3 MARCH study, the largest trial for PFIC, showing significant improvements in serum bile acids, pruritus, bilirubin, and growth metrics. LIVMARLI is already approved for treating cholestatic pruritus associated with Alagille syndrome. The company also submitted a supplemental application to the U.S. FDA for similar use in PFIC patients three months and older.
Mirum Pharmaceuticals announced that the FDA has approved a label expansion for LIVMARLI® (maralixibat), lowering the age requirement for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) from one year to three months. This change is supported by data from the RISE study on the safety and tolerability of LIVMARLI in infants. The approval allows early treatment for the majority of ALGS patients diagnosed before one year. Currently, LIVMARLI is also approved in Europe for patients aged two months and older. Mirum has also submitted a supplemental NDA for treating cholestatic pruritus in progressive familial intrahepatic cholestasis.
Mirum Pharmaceuticals (MIRM) announced on March 10, 2023, that its Compensation Committee granted inducement awards to four new employees, comprising stock options for 40,050 shares and 20,050 restricted stock units (RSUs) under its 2020 Inducement Plan. Each option has an exercise price of $22.30, matching the closing price on the grant date, and will vest over four years. The RSUs will vest over three years. Mirum is dedicated to treating rare liver diseases, with its chief product, LIVMARLI, approved for cholestatic pruritus in patients with Alagille syndrome. The company is advancing two investigational treatments for liver diseases.